7 results match your criteria: "Henry Ford Hospital West Bloomfield[Affiliation]"
Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial.
JAMA
September 2021
University of Ottawa, Ottawa, Ontario, Canada.
Article Synopsis
- The study aimed to evaluate whether increasing urate levels through inosine treatment can slow down the progression of early Parkinson's disease, using data that suggests urate elevation might be beneficial.* -
- Conducted as a phase 3 trial, 298 participants with early-stage Parkinson's disease were randomly assigned to receive either inosine to elevate serum urate levels or a placebo, over a period of up to 2 years.* -
- Results from the study indicated no significant differences in clinical progression rates between the inosine and placebo groups, leading to an early closure of the trial based on an interim analysis.*
Quality of life in isolated dystonia: non-motor manifestations matter.
J Neurol Neurosurg Psychiatry
February 2021
Department of Neurology, University of Luebeck, Luebeck, Germany
Objective: To evaluate the relationship between health-related quality of life (HR-QoL) and both physical and psychiatric factors in a large, international, multicentre cohort of patients with isolated dystonia, the Dystonia Coalition.
Methods: Natural history data from 603 patients with isolated dystonia (median age 57 years (IQR: 48 to 64 years), 67.0% women) were prospectively acquired and analysed.
Discharge Delays and Costs Associated With Outpatient Parenteral Antimicrobial Therapy for High-Priced Antibiotics.
Clin Infect Dis
October 2020
Department of Pharmacy Services, Henry Ford Hospital, Detroit, Michigan, USA.
Background: Outpatient parenteral antimicrobial therapy (OPAT) is a widely used, safe, and cost-effective treatment. Most public and private insurance providers require prior authorization (PA) for OPAT, yet the impact of the inpatient PA process is not known. Our aim was to characterize discharge barriers and PA delays associated with high-priced OPAT antibiotics.
View Article and Find Full Text PDFPimavanserin use in a movement disorders clinic: a single-center experience.
Neurol Sci
October 2018
Parkinson's Disease and Movement Disorders Center, Department of Neurology, Henry Ford Hospital West Bloomfield, 2799 W Grand Blvd., K-11, Detroit, MI, 48202, USA.
Background: Parkinson's disease psychosis (PDP) is a disabling non-motor symptom of Parkinson's disease (PD) that is challenging to treat. Dopamine receptor blockers (DRB) are used to treat PDP, though these may be associated with adverse effects, including worsening of Parkinsonism. Pimavanserin, a selective 5-HT receptor inverse agonist, was recently FDA-approved for treatment of PDP; however, there is limited information on its long-term use in PDP patients.
View Article and Find Full Text PDFPseudobulbar Affect Correlates With Mood Symptoms in Parkinsonian Disorders but Not Amyotrophic Lateral Sclerosis.
J Neuropsychiatry Clin Neurosci
November 2018
From the Parkinson Disease and Movement Disorders Clinic, Henry Ford Hospital West Bloomfield, Mich. (NP); the Department of Psychology, University of Kentucky, Lexington, K.Y. (HC); the Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, Tex. (MY, JJ-S); the ALS Association Center, Baylor College of Medicine, Houston, Tex. (MY); and the Department of Medicine, University of Alberta, Alberta, CA (CP).
Pseudobulbar affect (PBA) is a syndrome of affective disturbance associated with inappropriate laughter and crying, independent of mood. PBA is common in amyotrophic lateral sclerosis (ALS) and increasingly recognized in Parkinson's disease (PD) and atypical parkinsonism (aP). Correlates of PBA have not been systematically studied.
View Article and Find Full Text PDFPulmonary Safety and Tolerability of Inhaled Levodopa (CVT-301) Administered to Patients with Parkinson's Disease.
J Aerosol Med Pulm Drug Deliv
June 2018
3 Acorda Therapeutics, Inc. , Ardsley, New York.
Background: CVT-301, an inhaled levodopa (LD) formulation, is under development for relief of OFF periods in Parkinson's disease (PD). Previously, we reported that CVT-301 improved OFF symptoms relative to placebo. In this study, we evaluate pulmonary function in patients treated with a single dose of CVT-301 or placebo for 3 hours, or received multiple doses/day for 4 weeks.
View Article and Find Full Text PDF